The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Indian drugmaker Sun Industries’ Leqselvi ...

As with all clinical trials, the MHRA's top priority is the safety and wellbeing of the trial participants. An MHRA spokesperson said: "With all ...

Launched today by the Medicines and Healthcare products Regulatory Agency (the MHRA), the seventh annual #MedSafetyWeek is running until 13 November to encourage widespread public engagement and ...

Healthcare apps are becoming a greater part of everyday life. The increasing prominence and functionality of these apps has lead to the question of when healthcare apps should be regulated as medical ...

The MHRA has approved deuruxolitinib, marketed as Leqselvi, for the treatment of severe alopecia areata in adults, offering a new therapeutic option for people living with the autoimmune condition.

The UK Medicines and Healthcare products Regulatory Agency (MHRA's) has published a Statement of policy intent: international recognition of medical devices outlining its proposal for the ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s disease and ulcerative colitis (UC). Already used for plaque psoriasis and ...

The Medicines and Healthcare products Regulatory Agency (MHRA) will evaluate the possibility of extending recognition of CE-marked medical devices beyond the current 2030 deadline, marking a potential ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Leqselvi (deuruxolitinib), made by Sun Pharma UK, as a treatment for severe alopecia areata in adults. Alopecia areata is a ...